Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients

[1]  D. Price,et al.  The molecular basis for public T-cell responses? , 2008, Nature Reviews Immunology.

[2]  G. Gao,et al.  Crystallization and preliminary X-ray structural studies of a Melan-A pMHC-TCR complex. , 2007, Acta crystallographica. Section F, Structural biology and crystallization communications.

[3]  J. Schøller,et al.  Preferential usage of T‐cell receptor αβ variable regions among tumor‐infiltrating lymphocytes in primary human malignant melanomas , 2007 .

[4]  P. Doherty,et al.  Structural determinants of T-cell receptor bias in immunity , 2006, Nature Reviews Immunology.

[5]  D. Speiser,et al.  A Novel Approach to Characterize Clonality and Differentiation of Human Melanoma-Specific T Cell Responses: Spontaneous Priming and Efficient Boosting by Vaccination1 , 2006, The Journal of Immunology.

[6]  D. Speiser,et al.  Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex1 , 2006, The Journal of Immunology.

[7]  A. Perl,et al.  CD8+ T Cell-Mediated HLA-A*0201-Restricted Cytotoxicity to Transaldolase Peptide 168–176 in Patients with Multiple Sclerosis1 , 2005, The Journal of Immunology.

[8]  S. Migueles,et al.  Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses , 2005, The Journal of experimental medicine.

[9]  M. Bonneville,et al.  Selection of T Cell Clones Expressing High-Affinity Public TCRs within Human Cytomegalovirus-Specific CD8 T Cell Responses1 , 2005, The Journal of Immunology.

[10]  K. Echasserieau,et al.  Adoptive Transfer of Tumor-Reactive Melan-A-Specific CTL Clones in Melanoma Patients Is Followed by Increased Frequencies of Additional Melan-A-Specific T Cells1 , 2005, The Journal of Immunology.

[11]  G. Rossi,et al.  T-Cell Immune Reconstitution after Hematopoietic Stem Cell Transplantation for HIV-Associated Lymphoma , 2005, Transplantation.

[12]  Jérôme Lane,et al.  IMGT®, the international ImMunoGeneTics information system® , 2004, Nucleic Acids Res..

[13]  S. Rosenberg,et al.  Selective Growth, In Vitro and In Vivo, of Individual T Cell Clones from Tumor-Infiltrating Lymphocytes Obtained from Patients with Melanoma , 2004, The Journal of Immunology.

[14]  J. Becker,et al.  Circulation and homing of melanoma‐reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte‐derived dendritic cells , 2004, International journal of cancer.

[15]  J. Becker,et al.  T-cell clonotypes in cancer , 2004, Journal of Translational Medicine.

[16]  M. A. van der Hoorn,et al.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. , 2003, Blood.

[17]  F. Benvenuto,et al.  Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient. , 2003, The Journal of investigative dermatology.

[18]  E. Thiel,et al.  Restricted T-cell receptor repertoire in melanoma metastases regressing after cytokine therapy. , 2003, Cancer research.

[19]  M. Bonneville,et al.  Prevalent Role of TCR α-Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen1 , 2003, The Journal of Immunology.

[20]  F. Benvenuto,et al.  Dominant TCR-α Requirements for a Self Antigen Recognition in Humans , 2002, The Journal of Immunology.

[21]  M. Bonneville,et al.  Dominant TCR Vα  usage by virus and tumor‐reactive T cells with wide affinity ranges for their specific antigens , 2002, European journal of immunology.

[22]  G. Basso,et al.  Large and Dissimilar Repertoire of Melan-A/MART-1-Specific CTL in Metastatic Lesions and Blood of a Melanoma Patient1 , 2002, The Journal of Immunology.

[23]  Takami Sato,et al.  TCR Rearrangement in Lymphocytes Infiltrating Melanoma Metastases After Administration of Autologous Dinitrophenyl-Modified Vaccine1 , 2002, The Journal of Immunology.

[24]  A. Necker,et al.  Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis , 2002, Melanoma research.

[25]  R. Houghten,et al.  Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans , 2002, The Journal of experimental medicine.

[26]  F. Mami-Chouaib,et al.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Romero,et al.  Vaccination with a Melan-A Peptide Selects an Oligoclonal T Cell Population with Increased Functional Avidity and Tumor Reactivity1 , 2002, The Journal of Immunology.

[28]  J. Karbach,et al.  Peptide‐specific CD8+ T‐cell evolution in vivo: Response to peptide vaccination with Melan‐A/MART‐1 , 2002, International journal of cancer.

[29]  D. Schadendorf,et al.  Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine , 2002, Cancer Gene Therapy.

[30]  Ian A Wilson,et al.  The specificity of TCR/pMHC interaction. , 2002, Current opinion in immunology.

[31]  J. Cabaniols,et al.  Most α/β T Cell Receptor Diversity Is Due to Terminal Deoxynucleotidyl Transferase , 2001, The Journal of experimental medicine.

[32]  A. Necker,et al.  Human leucocyte antigen‐A2 restricted and Mycobacterium tuberculosis 19‐kDa antigen‐specific CD8+ T‐cell responses are oligoclonal and exhibit a T‐cell cytotoxic type 2 response cytokine‐secretion pattern , 2001, Immunology.

[33]  M. Karplus,et al.  Crystal Structures of Two Closely Related but Antigenically Distinct HLA-A2/Melanocyte-Melanoma Tumor-Antigen Peptide Complexes1 , 2001, The Journal of Immunology.

[34]  E. Schaftingen,et al.  High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. , 2001, Cancer research.

[35]  S. Shichijo,et al.  Molecular basis of T cell-mediated recognition of pancreatic cancer cells. , 2001, Cancer research.

[36]  P. Romero,et al.  Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoires. , 2001, Cancer research.

[37]  P. Selby,et al.  Persistence of clonal T‐cell expansions following high‐dose chemotherapy and autologous peripheral blood progenitor cell rescue , 2000, British journal of haematology.

[38]  M. Bonneville,et al.  Frequent Contribution of T Cell Clonotypes with Public TCR Features to the Chronic Response Against a Dominant EBV-Derived Epitope: Application to Direct Detection of Their Molecular Imprint on the Human Peripheral T Cell Repertoire1 , 2000, The Journal of Immunology.

[39]  S. Rosenberg,et al.  Quantitation of T-Cell Receptor Frequencies by Competitive Polymerase Chain Reaction: Dynamics of T-Cell Clonotype Frequencies in an Expanding Tumor-Infiltrating Lymphocyte Culture , 2000, Journal of immunotherapy.

[40]  F. Mami-Chouaib,et al.  Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung. , 2000, International immunology.

[41]  A. Anichini,et al.  High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition , 1999, Cancer Immunology, Immunotherapy.

[42]  H. Pehamberger,et al.  First comparative delineation of the T cell receptor repertoire in primary and multiple subsequent/coexisting metastatic melanoma sites. , 1998, The Journal of investigative dermatology.

[43]  S. Rowland-Jones,et al.  Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific , 1998, The Journal of experimental medicine.

[44]  M. Nishimura,et al.  T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. , 1997, Cancer research.

[45]  P. Romero,et al.  Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. , 1997, Journal of immunology.

[46]  G. Carcelain,et al.  Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. , 1997, Journal of immunology.

[47]  C. Farina,et al.  Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. , 1997, The Journal of clinical investigation.

[48]  C. Farina,et al.  Conserved TCR usage by HLA-Cw* 1601-restricted T cell clones recognizing melanoma antigens. , 1996, International immunology.

[49]  H. Zarour,et al.  The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. , 1996, The Journal of investigative dermatology.

[50]  P. Romero,et al.  Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1 , 1995, The Journal of experimental medicine.

[51]  C. Farina,et al.  Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Bell,et al.  Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment , 1995, The Journal of experimental medicine.

[53]  S. Rosenberg,et al.  Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. , 1994, Cancer research.

[54]  P. Kourilsky,et al.  Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. , 1994, Journal of immunology.

[55]  J. Cabaniols,et al.  Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice , 1994, The Journal of experimental medicine.

[56]  S. Rosenberg,et al.  T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Herlyn,et al.  T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone , 1993, The Journal of experimental medicine.

[58]  G. Carcelain,et al.  Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. , 1993, Cancer research.

[59]  M. Zöller,et al.  The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[60]  A. Mackensen,et al.  Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. , 1993, The Journal of clinical investigation.

[61]  J. Bell,et al.  Extensive conservation of alpha and beta chains of the human T-cell antigen receptor recognizing HLA-A2 and influenza A matrix peptide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[62]  C. Benoist,et al.  Islet-specific T-cell clones from nonobese diabetic mice express heterogeneous T-cell receptors. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[63]  F. Marincola,et al.  Chemotherapy enhances vaccine‐induced antitumor immunity in melanoma patients , 2009, International journal of cancer.

[64]  Alberto Albertini,et al.  Different TCRBV genes generate biased patterns of V-D-J diversity in human T cells , 2004, Immunogenetics.

[65]  Marie-Paule Lefranc,et al.  IMGT, The International ImMunoGeneTics Information System, http://imgt.cines.fr. , 2004, Methods in molecular biology.

[66]  F. Benvenuto,et al.  Dominant TCR-alpha requirements for a self antigen recognition in humans. , 2002, Journal of immunology.

[67]  M. Omine.  [HIV-associated lymphoma]. , 1998, Ryoikibetsu shokogun shirizu.

[68]  Marie-Paule Lefranc,et al.  IMGT, the international ImMunoGeneTics database. , 1997, Nucleic acids research.

[69]  J. Zeuthen,et al.  Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. , 1994, International journal of cancer.